Combined carrier status of prothrombin 20210A and factor XIII-A leu34 alleles as a strong risk factor for myocardial infarction: Evidence of a gene-gene interaction

Blood

Volumn 101, Issue 8, 2003, Pages 3037-3041

  Butt, Christopher ^b   Zheng, Hong ^b   Randell, Edward ^b   Robb, Desmond ^b   Parfrey, Patrick ^b   Xie, Ya Gang ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 5; PROTHROMBIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN;

ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PENETRANCE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; 5' UNTRANSLATED REGION; ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AMINO ACID SUBSTITUTION; CANADA; FOUNDER EFFECT; GENE LINKAGE DISEQUILIBRIUM; GENETIC EPISTASIS; GENETICS; MIDDLE AGED; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONSET AGE; POINT MUTATION; PROSPECTIVE STUDY; SEX DIFFERENCE; THROMBOPHILIA;

5' UNTRANSLATED REGIONS; ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE OF ONSET; AGED; ALLELES; AMINO ACID SUBSTITUTION; DNA MUTATIONAL ANALYSIS; EPISTASIS, GENETIC; FACTOR V; FACTOR XIII; FEMALE; FOUNDER EFFECT; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYOCARDIAL INFARCTION; NEWFOUNDLAND; POINT MUTATION; PREVALENCE; PROSPECTIVE STUDIES; PROTHROMBIN; RISK FACTORS; SEX FACTORS; THROMBOPHILIA;

EID: 0038620365     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2888     Document Type: Article

References (35)

1. Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000;149:251-266.
2. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
3. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
5. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997;98:353-355.
6. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
7. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation. 1998;97:1037-1041.
8. Arruda VR, Siquiera LH, Chiaparini LC, et al. Prevalence of the prothrombin gene variant 20210 G → A among patients with myocardial infarction. Cardiovasc Res. 1998;37:42-45.
9. Franco RF, Trip MD, ten Cate H, et al. The 20210 G → A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol. 1999;104:50-54.
10. Russo C, Girelli D, Olivieri O, et al. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation. 2001;103:2436-2440.
11. Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost. 1999;81:861-864.
12. Emmerich J, Poirier O, Evans A. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance [abstract]. Lancet. 1995;345:321.
13. van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V [abstract]. Nat Med. 1995;1:185.
14. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg 506γ-Gln) mutation in young survivors of myocardial infarction. Thromb Haemost. 1996;75:701-702.
15. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
16. Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol. 2000;36:717-722.
17. Mansourati J, Da Costa A, Munier S, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost. 2000;83:822-825.
18. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998;79:8-13.
19. Wartiovaara U, Perola M, Mikkola H, et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis. 1999;142:295-300.
20. Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA, Zago MA. Factor XIII val34leu and the risk of myocardial infarction. Haematologica. 2000;85:67-71.
21. Renner W, Brodmann M, Pabst E, Stanger O, Wascher TC, Pilger E. The V34L polymorphism of factor XIII and peripheral arterial disease. Int Angiol. 2002;21:53-57.
22. Corral J, Gonzalez-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica. 2000;85:293-297.
23. Canavy I, Henry M, Morange PE, et al. Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost. 2000;83:212-216.
24. Aleksic N, Ahn C, Wang YW, et al. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2002;22:348-352.
25. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 1998;92:2766-2770.
26. Balogh I, Szoke G, Karpati L, et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood. 2000;96:2479-2486.
27. Martin LJ, Crawford MH, Koertvelyessy T, Keeping D, Collins M, Huntsman R. The population structure of ten Newfoundland outports. Hum Biol. 2000;72:997-1016.
28. Bear JC, Nemec TF, Kennedy JC, et al. Persistent genetic isolation in outport Newfoundland. Am J Med Genet. 1987;27:807-830.
29. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells [abstract]. Nucleic Acids Res. 1988;16:1215.
30. Linfert DR, Rezuke WN, Tsongalis GJ. Rapid multiplex analysis for the factor V Leiden and prothrombin G20210A mutations associated with hereditary thrombophilia. Conn Med. 1998;62:519-525.
31. Girolami A, Simioni P, Scarano L, Carraro G. Prothrombin and the prothrombin 20210 G to A polymorphism: their relationship with hypercoagulability and thrombosis. Blood Rev. 1999;13:205-210.
32. Zheng H, Tzeng C-C, Butt C, Randell E, Xie Y-G. Extremely low prevalence of factor V Leiden, FII20210A, and FXIIIV34L in Chinese population. Thromb Haemost. 2002;87:1081-1082.
33. Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J, Clegg JB. Born to clot: the European burden. Br J Haematol. 1999;105:564-566.
34. Gurgey A, Kudayarov DK, Tuncer M, Parlak H, Altay C. The factor V Leiden and prothrombin G20210A mutations in Kirghiz population [abstract]. Thromb Haemost. 2000;84:356.
35. Zabalegui N, Montes R, Orbe J, et al. Prevalence of FVR506Q and prothrombin 20210A mutations in the Navarrese population. Thromb Haemost. 1998;80:522-523.